semaglutide 2.4 mg weekly A higher-dose of Wegovy has received final regulatory clearance in the EU, marking a significant step for obesity treatment. The approval allows physicians to prescribe a 7.2 dose, administered as Order WEGOVY® FLEXTOUCH® 2.4mg (Italian)

On a 1 mg weekly dose, these firm, raised nodules appeared within minutes but disappeared within 2-4 days

Healthcare providers usually monitor lipid panels at baseline and after 3-6 months to assess treatment response

Adv Chronic Kidney Dis 25(2):121132

Weight Loss with Semaglutide Average loss: 1416% of body weight Key trial: STEP 1 (New England Journal of Medicine) Population: Obese individuals without diabetes Notable: Significant appetite suppression and better cardiometabolic parameters reported by most participants Weight Loss with Tirzepatide Average loss: 21% or more of body weight at highest dose (15 mg) Key trial: SURMOUNT-1 Population: Obese and overweight adults without diabetes Remarkable: Highest rate of any FDA-approved weight loss medication to date Clinical Insight: Tirzepatide always beats Semaglutide in weight reduction